Athira Pharma tanks following fosgonimeton study missing primary endpoint Check out this morning's top movers from around Wall Street, compiled by The Fly.
HIGHER -
- Ambarella (AMBA) up 1% after the company and Inceptio Technology announced that Inceptio selected two each of Ambarella's CV2FS and CV2AQ edge AI systems on chip, or SoCs, a total of four CVflow SoCs, for its automotive-grade central computing platform
- Paratek Pharmaceuticals (PRTK) up 5% after announcing the FDA has granted Fast Track designation for the oral and IV formulations of the company's novel, broad-spectrum antibiotic Nuzyra, omadacycline, for the treatment of pulmonary Nontuberculous Mycobacterial NTM disease caused by both Mycobacterium avium complex and Mycobacterium abscessus
- New Relic (NEWR) up 1% after Jana Partners disclosed a 5.3% stake in the company, which represents over 3.52M shares
UP AFTER EARNINGS -
- Korn/Ferry (KFY) up 3%
- Winnebago (WGO) up 2%
- La-Z-Boy (LZB) up 8%
LOWER -
- Athira Pharma (ATHA) down 68% after the company announced that its topline results from its exploratory ACT-AD Phase 2 study of fosgonimeton in patients with mild-to-moderate Alzheimer's disease did not meet the primary endpoint
- Airbnb (ABNB) down 3% after JMP Securities analyst Nicholas Jones downgraded the stock to Market Perform without a price target after taking over coverage of the name
- Dow Inc. (DOW) down 5% after Credit Suisse analyst John Roberts downgraded shares to Underperform from Neutral with a price target of $49, down from $67
- PulteGroup (PHM) down 3% after RBC Capital analyst Mike Dahl downgraded the stock to Sector Perform from Outperform with a price target of $41, down from $56
Symbols:
AMBA PRTK NEWR KFY WGO LZB ABNB DOW PHM ATHA Keywords: Fly Intel, Wall Street, Top Stories, Stocks